ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Andrew J. Graham
Sean C. Grondin
Richard J. Finley
Joanne Clifton
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graham, A. J.
Right arrow Articles by Clifton, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graham, A. J.
Right arrow Articles by Clifton, J.
Related Collections
Right arrow Esophagus - cancer
Right arrowRelated Article

Ann Thorac Surg 2007;83:1257-1264
© 2007 The Society of Thoracic Surgeons

Original Articles: General Thoracic

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis

Andrew J. Graham, MD, MSa,b,*, Fiona M. Shrive, PhDb, William A. Ghali, MD, MPHb,c, Braden J. Manns, MD, MSb,c,d, Sean C. Grondin, MD, MPHa, Richard J. Finley, MDd, Joanne Clifton, MSd

a Department of Surgery, Division of Thoracic Surgery, University of Calgary, Institute of Health Economics, Calgary, Alberta
b Department of Community Health Sciences, University of Calgary, Institute of Health Economics, Calgary, Alberta
c Department of Medicine, University of Calgary, Institute of Health Economics, Calgary, Alberta
d Division of Thoracic Surgery, University of British Columbia, Vancouver, British Columbia, Canada

Accepted for publication November 13, 2006.

* Address correspondence to Dr Graham, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9 (Email: andrew.graham{at}calgaryhealthregion.ca).

Background: The objective of this study was to combine systematic review and decision analytic techniques to determine the optimal treatment strategy for patients with locally advanced esophageal cancer.

Methods: We performed a systematic review of all randomized trials of patients with locally advanced esophageal cancer that included one of the following strategies compared with surgery alone: chemoradiotherapy followed by surgery, chemotherapy followed by surgery, or surgery with adjuvant chemoradiotherapy. Using the estimates of relative risk for mortality and overall quality of life we constructed a decision model. The outcome of interest was expected quality-adjusted life-years (QALY).

Results: The meta-analysis showed for the first year, the relative risk (95% confidence interval) of death for treatments compared with surgery were 0.87 (0.75 to 1.02) for chemoradiotherapy followed by surgery, 0.94 (0.82 to 1.08) for chemotherapy followed by surgery, and 1.33 (0.93 to 1.93) for surgery with adjuvant chemoradiotherapy. The QALYs gained for surgery alone, chemoradiotherapy followed by surgery, chemotherapy followed by surgery, and surgery with adjuvant chemoradiotherapy strategies were 2.07, 2.18, 2.14, and 1.99, respectively. If the reduction in utility for multimodality treatment was increased to 21%, the QALYs gained for surgery alone, chemoradiotherapy followed by surgery, chemotherapy followed by surgery, and surgery with adjuvant chemoradiotherapy were 2.07, 2.03, 1.99, and 1.85, respectively.

Conclusions: Chemoradiotherapy followed by surgery appears to be associated with the best survival and the largest expected gain in QALYs. However, the improvement in quality-adjusted life expectancy is modest at 40 days, and surgery alone becomes the preferred strategy if the reduction in utility associated with multimodality treatment is increased to 21%.


Related Article

Invited commentary
William Burfeind, Jr
Ann. Thorac. Surg. 2007 83: 1264. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann OncolHome page
T. Ruhstaller, L. Widmer, J. C. Schuller, A. Roth, V. Hess, W. Mingrone, R. von Moos, M. Borner, B. C. Pestalozzi, S. BalmerMajno, et al.
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ann. Onc., September 1, 2009; 20(9): 1522 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tepper, M. J. Krasna, D. Niedzwiecki, D. Hollis, C. E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, and R. Mayer
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
J. Clin. Oncol., March 1, 2008; 26(7): 1086 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
W. Burfeind Jr
Invited commentary
Ann. Thorac. Surg., April 1, 2007; 83(4): 1264 - 1264.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The Society of Thoracic Surgeons.